Aligos Therapeutics, Inc.

Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same. Also provided herein are methods of treating diseases and/or conditions with a compound of Formula (I), or a pharmaceutically acceptable salt thereof.

Disclosed herein are methods of modulating the activity of a thyroid hormone receptor beta and methods of treating disease using a pyridazinone compound.

Disclosed herein are pharmaceutical compositions comprising a compound of Formula I: or a stereoisomer or a tautomer thereof, or a pharmaceutically acceptable salt thereof, and one or more surfactants, and methods of treating disease by administering or contacting a subject with one or more of the above pharmaceutical compositions.

Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same. Also provided herein are methods of treating diseases and/or conditions with a compound of Formula (I), or a pharmaceutically acceptable salt thereof.

Provided herein are compounds that can be useful as inhibitors of PD-1, PD-L1 or the PD-1/PD-L1 interaction. Also provided herein are pharmaceutical compositions of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and methods of using a compound of Formula (I), or a pharmaceutically acceptable salt thereof, for the treatment of PD-L1 related diseases including but not limited to liver diseases, cancer, hepatocellular carcinoma, viral diseases, or hepatitis B.

Described are short interfering nucleic acid (siNA) molecules comprising modified nucleotides, compositions, and methods and uses thereof.

The present application relates to derivatives of STOPS™ antiviral compounds having enhanced helicity, wherein the compounds are S-antigen transport inhibiting oligonucleotide polymers. This application further relates to processes for making the compounds and methods of using them to treat diseases and conditions. In some embodiments, the diseases and conditions are related to hepatitis B and/or hepatitis D.

Provided herein are antisense oligonucleotides and compositions that include the disclosed ASOs. The disclosed ASOs and compositions can be used for treating hepatitis B.

Disclosed herein are methods of preparing modulators of THR-β.

Described are short interfering nucleic acid (siNA) molecules comprising modified nucleotides, compositions, and methods and uses thereof.